Informações: Esta não é a versão mais recente do modelo de dados. Uma visão geral da versão pode ser encontrada à esquerda em Versões. Para a versão mais recente, clique aqui.
Informações:
Falhas:
ID
13870
Descrição
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00907959
Link
https://clinicaltrials.gov/show/NCT00907959
Palavras-chave
Versões (2)
- 13/03/2016 13/03/2016 -
- 20/09/2021 20/09/2021 -
Transferido a
13 de março de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Metastatic Breast Cancer NCT00907959
Eligibility Metastatic Breast Cancer NCT00907959
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT00907959
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
female; age
Item
1. women 18 years or older.
boolean
C0015780 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Pathology report breast cancer
Item
2. histologically confirmed diagnosis of breast cancer based on pathology report of primary, regional or metastatic breast cancer.
boolean
C0807321 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0678222 (UMLS CUI [1,2])
metastases
Item
3. clinical evidence of metastatic (stage iv) involvement other than bone only metastasis based on the investigator's clinical and/or radiographic findings.
boolean
C0027627 (UMLS CUI [1])
estrogen receptor; progesterone receptor; biopsy tissue
Item
4. availability of estrogen receptor and progesterone receptor status measured on biopsy tissue. (status on the most recent biopsy where er/pr status was documented will be used to determine hormone receptor status for stratification).
boolean
C2919271 (UMLS CUI [1])
C0034833 (UMLS CUI [2])
C3864006 (UMLS CUI [3])
C0034833 (UMLS CUI [2])
C3864006 (UMLS CUI [3])
Measurable Disease; bone lesion; leptomeningeal disease; ascites
Item
5. at least one measurable disease site defined by recist criteria, with measurement made within 30 days of beginning study therapy. (non-measurable disease includes bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed and followed by imaging techniques, and cystic lesions. for lesions in a previously irradiated field, the radiated lesion cannot be assessed as a measurable lesion unless growth of that lesion has been documented after radiation).
boolean
C1513041 (UMLS CUI [1])
C0238792 (UMLS CUI [2])
C3160796 (UMLS CUI [3])
C0003962 (UMLS CUI [4])
C0238792 (UMLS CUI [2])
C3160796 (UMLS CUI [3])
C0003962 (UMLS CUI [4])
Cytotoxic agent; exogenous hormone therapy; adjuvant therapy Carcinoma breast stage IV
Item
6. no more than 2 prior cytotoxic regimens administered for metastatic breast cancer. (participants may have received any number of exogenous hormone therapies for stage iv disease and/or adjuvant therapy).
boolean
C0304497 (UMLS CUI [1])
C1516999 (UMLS CUI [2])
C0677850 (UMLS CUI [3,1])
C0278488 (UMLS CUI [3,2])
C1516999 (UMLS CUI [2])
C0677850 (UMLS CUI [3,1])
C0278488 (UMLS CUI [3,2])
life expectancy
Item
7. life expectancy of >12 weeks.
boolean
C0023671 (UMLS CUI [1])
ecog
Item
8. eastern cooperative oncology group performance status <2.
boolean
C1520224 (UMLS CUI [1])
Contraception status
Item
9. women of child bearing potential must agree to use two adequate methods of contraception or abstain from sexual intercourse during study treatment. acceptable methods of contraception are as follows:
boolean
C0420837 (UMLS CUI [1])
intrauterine device
Item
1. intrauterine device (iud)
boolean
C0021900 (UMLS CUI [1])
hormonal birth control
Item
2. hormonal birth control
boolean
C2985296 (UMLS CUI [1])
tubal ligation
Item
3. tubal ligation
boolean
C0520483 (UMLS CUI [1])
vasectomy
Item
4. partner's vasectomy
boolean
C0042387 (UMLS CUI [1])
latex condom
Item
5. latex condom
boolean
C3873750 (UMLS CUI [1])
diaphragm
Item
6. diaphragm
boolean
C0042241 (UMLS CUI [1])
cervical cap
Item
7. cervical cap
boolean
C0007848 (UMLS CUI [1])
organ function; bone marrow function
Item
10. adequate organ and marrow function measured within 14 days of study treatment as defined below:
boolean
C0678852 (UMLS CUI [1])
C0412480 (UMLS CUI [2])
C0412480 (UMLS CUI [2])
absolute neutrophil count; platelets; hemoglobin; total bilirubin; alt- ast ratio; serum creatinine
Item
absolute neutrophil count >1,500 cells/mm3 platelets >100,000 cells/mm3 hemoglobin >10 g/dl total bilirubin <1.5 mg/dl ast(sgot)/alt(sgpt) <2.5 x institutional upper limit of normal or <5 x normal with documented liver metastasis alkaline phosphatase <3 x institutional upper limit of normal or <5 x normal with documented liver or bone metastasis serum creatinine <1.5 mg/dl or creatinine clearance >60 ml/min/1.73 m2 for participants with serum creatinine levels above institutional normal.
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0201913 (UMLS CUI [4])
C3831581 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C0201913 (UMLS CUI [4])
C3831581 (UMLS CUI [5])
C0201976 (UMLS CUI [6])